Publication: Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper
1
Issued Date
2007-10-18
Resource Type
ISSN
07317085
Other identifier(s)
2-s2.0-34848926084
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Pharmaceutical and Biomedical Analysis. Vol.45, No.2 (2007), 282-287
Suggested Citation
D. Blessborn, S. Römsing, A. Annerberg, D. Sundquist, A. Björkman, N. Lindegardh, Y. Bergqvist Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. Journal of Pharmaceutical and Biomedical Analysis. Vol.45, No.2 (2007), 282-287. doi:10.1016/j.jpba.2007.07.015 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/24332
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper
Abstract
A bioanalytical method for the determination of lumefantrine in 100 μl blood applied onto sampling paper, by solid-phase extraction and liquid chromatography, has been developed and validated. Whatman 31 ET Chr sampling paper was pre-treated with 0.75 M tartaric acid before sampling capillary blood to enable a high recovery of lumefantrine. Lumefantrine was extracted from the sampling paper, then further purified using solid-phase extraction and finally quantified with HPLC. The between-day variation was below 10% over the range 0.4-25 μM. The lower limit of quantification was 0.25 μM in 100 μl capillary blood. No decrease in lumefantrine concentration in dried blood spot is seen after 4 months storage at 22 °C. The method was also evaluated in field samples from patients in Tanzania after treatment with lumefantrine/artemether. Lumefantrine could be estimated accurately enough to assess bioavailability and treatment compliance on day 7 (i.e. 4 days after the last dose) after a standard regimen with the lumefantrine/artemether combination. © 2007 Elsevier B.V. All rights reserved.